Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic affecting more than 10 million people worldwide and more than 2.5 million in the United States.[@bib0001] Although the reported case-fatality rates have been variable,[@bib0002] in-hospital mortality has been reported to be as high as 21%.[@bib0003] Several risk factors have been reported to be associated with worse disease and outcomes. Preexisting cardiac comorbid conditions and acute cardiac complications from COVID-19 correlated with more severe disease and higher fatality rates.[@bib0004] ^,^ [@bib0005] Small cohort studies have described the association between cardiovascular disease and cardiac injury with outcomes in patients with COVID-19, but data is still limited.[@bib0006] We present the largest comprehensive study looking at myocardial injury and mortality in patients with COVID-19 in the U.S. This study aims to evaluate outcomes of U.S. patients with cardiovascular comorbidities, determine factors associated with cardiac injury, and examine the association of cardiac injury with the severity of illness in patients with COVID-19.

Methods {#sec0001}
=======

Patients admitted to Henry Ford Health System, a tertiary care center in Southeast Michigan, USA, between March 9 and April 15, 2020, was included in the study. Patients selected were ≥18 years of age, diagnosed with SARS-CoV-2, and hospitalized. Patients were excluded if high-sensitivity troponin (hs-cTnI) levels were not obtained, they were transferred to or out of our center, or developed cardiac arrest before presentation. Records were retrospectively reviewed. This study was approved by the Institutional Review Board (IRB\# 13774), and informed consent was waived.

SARS-CoV-2 was diagnosed by onsite molecular diagnostic testing for the identification of SARS-CoV-2 RNA using RT-PCR (NeuMoDx assay). This method has been validated against the Centers for Disease Control and Prevention reference method[@bib0007] to meet or exceed the level of detection required under the Food and Drug Administration and Emergency Use Authorization guidelines.

The epidemiological, clinical, and laboratory data were manually extracted from electronic health records. Symptoms were deemed positive if endorsed within 24 hours of presentation. Comorbid conditions were identified based on admission and discharge diagnoses. Baseline levels refer to initial blood samples collected in the emergency department (ED) or the first values within 24 hours of admission. Patients admitted with COVID-19 had hs-cTnI (Beckman-Coulter) and inflammatory markers such as D-dimer, lactate dehydrogenase, ferritin, and C-reactive protein performed in the ED. These laboratory tests were repeated after 48 hours. Serial testing, however, was performed earlier based on an abnormal initial result at the discretion of the responsible provider. Peak concentrations referred to the highest laboratory value before the corresponding outcome. Imaging findings were described in accordance to Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19.[@bib0008]

Cardiac injury was defined as hs-cTnI concentration \>18ng/L, which is \>99th percentile of the upper limit of normal. Hs-cTnI, D-dimer, ferritin, lactate dehydrogenase, and C-reactive protein levels were documented at presentation, and then at peak during hospitalization. Acute kidney injury was defined according to the "Kidney Disease: Improving Global Outcomes" criteria for creatinine.[@bib0009] Acute respiratory distress syndrome (ARDS) was diagnosed, and its severity defined based on the Berlin definition.[@bib0010]

Data collected from electronic medical records were analyzed using Statistical Package for Social Sciences (SPSS, version 25, IBM, Armonk, New York). Descriptive statistical analysis was obtained for all included study variables and are summarized in [Table 1](#tbl0001){ref-type="table"} . Categorical variables were described by frequency and percentages, and continuous variables were defined by the median and interquartile range. Patient characteristics were compared using analysis of variance or Kruskal Wallis test for continuous variables based on the normality of the data, and chi-square test or Fisher exact tests for categorical variables. Univariate analysis was first performed to identify the significant variables associated with cardiac injury and mortality on admission. Multivariable and multivariate logistic regression analyses were then performed to identify significant predictors of mortality. Candidate variables for model inclusion included clinically relevant variables associated with COVID-19 mortality [@bib0011] ^,^ [@bib0012] and those with a p-value ≤0.05 on univariable analysis, with model exit criteria p-value ≥0.1. Time-to-event analysis was done using Kaplan-Meier curves for patients with and without cardiac injury stratified by initial hs-cTnI levels, first abnormal hs-cTnI, and maximum hs-cTnI levels. Post-hoc testing was done and a Benjami-Hochberg adjustment was applied to control for type 1 error. Log-rank test was used to identify any difference between the 3 groups of interest. Statistical analyses were considered significant if p ≤ 0.05.Table 1Clinical characteristics of patients on presentation according to cardiac injuryTable 1VariableOverallCardiac injuryp-valueYesNoTotal number of observations1020390 (38%)630 (6%) Age (years)63 (52--73)70 (51--89)59 (39--79) ≥65471 (46%)256 (66%)215 (34%)\<0.001 Female--- No. (%)511 (50%)161 (41%)350 (56%)\<0.001 White race403 (40%)152 (39%)251 (40%)0.312 Black race463 (45%)171 (44%)292 (46%) Other race categories154 (15%)67 (17%)87 (14%) Body mass index (kg/m^2^)31 (20-42)30 (19-41)32 (21-43)\<0.001 \<1819 (2%)2 (0.3%)17 (4%) 18--30419 (41%)246 (39%)173 (44%) 30--40398 (39%)254 (40%)144 (37%) \>40184 (18%)128 (20%)56 (14%)Symptoms at Admission Chest pain156 (15%)46 (12%)110 (18%)0.021 Fever539 (53%)176 (45%)363 (58%)\<0.001 Cough679 (67%)226 (58%)453 (72%)0.001 Myalgias250 (25%)74 (19%)176 (28%)0.001 Dyspnea686 (67%)243 (62%)443 (70%)0.008 GI symptoms366 (36%)127 (33%)239 (38%)0.103Comorbidities Hypertension742 (73%)333 (85%)409 (65%)\<0.001 Diabetes mellitus452 (44%)191 (49%)261 (41%)0.020 Heart failure127 (13%)97 (25%)30 (5%)\<0.001 Coronary artery disease123 (12%)80 (21%)43 (7%)\<0.001 Atrial fibrillation/flutter66 (7%)48 (12%)18 (3%)\<0.001 Any cardiovascular disease268 (26%)174 (45%)94 (15%)\<0.001 Cerebrovascular Disease59 (12%)39 (20%)20 (7%)\<0.001 Chronic kidney disease308 (30%)197 (51%)111 (18%)\<0.001 Smoker361 (25%)165 (42%)199 (31%)0.001 COPD105 (10%)50 (13%)55 (9%)0.040 Obstructive sleep apnea90 (9%)45 (12%)45 (7%)0.025 Asthma104 (10%)22 (6%)82 (13%)\<0.001 Chronic hypoxic respiratory failure30 (3%)16 (4%)14 (2%)0.083 Immunosuppression155 (15%)74 (19%)81 (13%)0.008 Cirrhosis8 (0.8%)5 (1%)3 (0.5%)0.150Medications Antiplatelet327 (32%)167 (43%)160 (25%)\<0.001 Anticoagulant96 (9%)64 (16%)32 (5%)\<0.001 ACEi/ ARB360 (35%)170 (44%)190 (30%)\<0.001 Beta blocker137 (27%)87 (44%)50 (16%)\<0.001 Calcium channel blockers150 (30%)76 (38%)74 (24%)0.001 Statin417 (41%)183 (47%)234 (37%)0.007 Diuretic99 (20%)64 (324%)35 (11%)\<0.001 Systemic steroids46 (5%)14 (4%)32 (5%)0.260 Immunosuppressant41 (4%)13 (3%)28 (4%)0.380 Insulin use158 (16%)74 (20%)84 (14%)0.020Laboratory data Sodium (mmol/L)135 (133--138)136 (133--139)135 (133--138)0.08 Potassium (mmol/L)3.9 (3.6--4.4)4.0 (3.7--4.5)3.9 (3.5--4.2)\<0.001 Bicarbonate (mmol/L24 (22--26)23 (20--25)24 (22--26)\<0.001 BUN (mg/dL)19 (13--33)30 (19--48)15 (11--22)\<0.001 Creatinine (mg/dL)1.1 (0.9--1.7)1.6 (1.2--3.0)1.0 (0.8--1.4)\<0.001 GFR (ml/min)69 (40--93)44 (21--68)81 (57--101)\<0.001 WBC (K/µL)6.4 (4.7--8.9)6.8 (4.9--10.3)6.4 (5.0--8.8)0.096 Hemoglobin (g/dL)13.0 (11.8--14.3)12.7 (11.2--14.4)13 (12--14)\<0.001 Neutrophil Count (K/µL)4.8 (3.3--7.1)5.3 (3.7--8.9)4.9 (3.3--6.8)0.006 Lymphocyte count (K/µL)0.90 (0.60--1.20)0.8 (0.5--1.2)0.9 (0.7--1.3)\<0.001 Platelet count (K/µL)200 (154--269)197 (146--263)216 (169--280)\<0.001 AST (IU/L)37 (26--58)44 (29--66)34 (24--52)\<0.001 ALT (IU/L)24 (15--38)25 (15--41)24 (16--36)0.915 Total bilirubin (mg/dL)0.6 (0.4--0.8)0.6 (0.4--0.9)0.6 (0.4--0.8)0.002 Albumin (mg/dL)3.5 (3.2--3.8)3.4 (3.1--3.7)3.6 (3.3--3.8)\<0.001 LDH (IU/L)350 (264--475)400 (287--533)334 (254--452)\<0.001 CPK (IU/L)183.0 (90--429)263 (133--625)151 (77--323)\<0.001 CRP (mg/dL)9.7 (4.8--15.7)12.0 (7.0--19.1)8.8 (3.1--14.9)\<0.001 Ferritin (ng/ml)540 (263--1078)658 (309--1294)425 (203--916)\<0.001 D-dimer (µg/ml)1.30 (0.7--2.5)1.9 (1.1--3.8)1.1 (0.6--2.1)\<0.001 High sensitivity troponin (ng/L)16.5 (6.2--32.0)43 (27-87)8.0 (2.3-14)\<0.001Chest imaging findings Normal144 (14%)56 (14%)88 (14%)0.153 Unilateral pneumonia135 (13%)54 (14%)81 (13%) Bilateral pneumonia224 (22%)71 (18%)153 (24%) Multi-focal pneumonia308 (49%)209 (54%)517 (51%)[^1]

Results {#sec0002}
=======

One thousand and forty-four patients met the initial inclusion criteria. Four patients who developed cardiac arrest or intubation before presentation or were transferred to and out of our center were excluded. Twenty patients without hs-cTnI levels were also excluded. A total of 1,020 patients were included in the final analysis. Baseline characteristics included a median age of 63 (52--73) years, body mass index (BMI) of 31 (20--42) kg/m^2^, 511 (50%) were female, and 403 (40%) were Caucasian. Additional characteristics are detailed in [Table 1](#tbl0001){ref-type="table"}.

Of those included in the final analysis, 390 (38%) demonstrated cardiac injury on presentation to the ED. In these patients, the median age was 70 (51--89) years, BMI 30 (19--41) kg/m^2^, 161 (41%) were female, and 152 (39%) were white. Patients with cardiac injury were noted to have a higher burden of cardiac risk factors including hypertension, diabetes mellitus, heart failure, coronary artery disease, atrial fibrillation/flutter, and cerebrovascular disease. Patients in this group were more likely to be smokers or have a history of pulmonary or kidney disease ([Table 1](#tbl0001){ref-type="table"}). Baseline laboratory data, including inflammatory markers, were compared between both groups. Patients with cardiac injury had higher median levels of lactate dehydrogenase, C-reactive protein, ferritin, and D-dimer. There were no significant differences on chest X-ray or CT chest imaging findings ([Table 1](#tbl0001){ref-type="table"}).

Using presenting hs-cTnI trends, patients with higher levels by categories ≤18 ng/L, \>18--99 ng/L, and ≥100 ng/L were more likely to develop in-hospital complications and adverse events including acute kidney injury, need for renal replacement therapy, mechanical ventilation, ICU transfer, and mortality ([Table 2](#tbl0002){ref-type="table"}). A nondetectable hs-cTnI on presentation did not rule out significant events (15% risk for the need for mechanical ventilation or death, [Table 2](#tbl0002){ref-type="table"}).Table 2In-hospital outcomes categorized according to presenting levels of high sensitivityTable 2VariablePresenting high sensitivity troponin levels (ng/L)p-valueUndetectable \<2.3 (n = 80)2.3--18 (n = 550)\>18--99 (n = 303)≥ 100 (n = 87)Hs-cTnI level (ng/L)2.3 (2.3--2.3)9 (5--16)35 (25--51)186 (129--334)\<0.001Acute kidney injury21 (26%)157 (29%)175 (58%)49 (56%)\<0.001Renal replacement therapy2 (3%)8 (2%)18 (6%)8 (9%)\<0.001Intensive care unit transfer9 (11%)84 (16%)76 (25%)29 (34%)\<0.001ARDS7 (9%)54 (10%)62 (21%)31 (36%)\<0.001 Mild1 (1%)8 (2%)10 (3%)6 (7%)\<0.001 Moderate2 (3%)25 (5%)18 (6%)10 (12%) Severe5 (6%)23 (4%)33 (11%)16 (18%)Mechanical ventilation10 (13%)59 (11%)68 (22%)32 (37%)\<0.001Mortality7 (9%)45 (8%)84 (28%)44 (51%)\<0.001Mechanical ventilation, and death12 (15%)110 (20%)122 (40%)57 (66%)\<0.001ICU, mechanical ventilation, and death12 (15%)110 (20%)303 (40%)87 (66%)\<0.001[^2]

Multivariate logistic regression analysis identified the clinical data elements independently predictive of mortality using comorbidities, peak values of laboratory data, and inpatient complications. These independent predictors included age ≥65, atrial fibrillation, cerebrovascular disease, D-dimer quartiles, hs-cTnI categories (≤18, \>18--99, and ≥100 ng/L), and ARDS. Clinical data elements included in the multivariate analysis are detailed in [Table 3](#tbl0003){ref-type="table"} .Table 3Predictors of inpatient mortality after multivariate regression using patient risk factors, inpatient complications as well as peak serum biomarkers levelsTable 3VariablesOdds ratio (95% confidence interval)p-valueAge ≥ 65 (years)3.9 (2.2--6.7)\<0.001Atrial fibrillation/flutter2.5 (1.2--5.3)0.014Cerebrovascular disease2.5 (1.3--5.0)0.008Peak D-dimer \< 1 µg/mlReference0.013Peak D-dimer ≥ 1 \< 1.8 µg/ml1.2 (0.4--3.7)0.696Peak D-dimer ≥ 1.8 \< 4 µg/ml2.7 (1.0--7.4)0.049Peak D-dimer ≥ 4 µg/ml3.3 (1.2--9.0)0.017Peak high sensitivity troponin ≤ 18 ng/LReference\<0.001Peak high sensitivity troponin 19--99 ng/L3.0 (1.5--6.0)0.002Peak high sensitivity troponin ≥100 ng/L7.7 (3.7--16.0)\<0.001Acute respiratory distress syndrome14.6 (8.2--25.7)\<0.001[^3][^4]

The Kaplan-Meier curves in [Figure 1](#fig0001){ref-type="fig"} demonstrate the survival probability between patient groups according to the incidence of cardiac injury. Patients with injury on presentation have a lower survival probability than those who develop cardiac injury later in their stay (adjusted log-rank p=0.012), and both have a lower survival probability than those who never develop cardiac injury (adjusted log-rank p \< 0.001 and p=0.003, respectively) ([Figure 1](#fig0001){ref-type="fig"}).Figure 1Survival probability of patients according to cardiac injury incidence categories. Kaplan Meier survival curves reveal the survival probability of patients according to cardiac injury incidence categories. Patients with injury on presentation (*C*), (red) have a lower survival probability than those who develop cardiac injury later in their stay (*B*), (purple) (adjusted log-rank p=0.012), and both have a lower survival probability than those who never develop cardiac injury (*A*), (green) (adjusted log-rank p \<0.001 and p=0.003, respectively). Cardiac injury was defined by a hs-cTnI concentration \>99th percentile.Figure 1

Discussion {#sec0003}
==========

This is one of the largest studied cohorts in the U.S. describing cardiac injury and its associated outcomes in patients hospitalized with COVID-19. Patients with cardiovascular risk factors (older age, hypertension, diabetes) and cardiovascular disease (coronary artery disease, heart failure, atrial fibrillation, and cerebrovascular disease) were at an increased risk of developing cardiac injury. Subsequently, those with cardiac injury were associated with a higher risk of intensive care unit admission, mechanical ventilator support, and mortality. These findings are similar to the reports published in Chinese cohorts.[@bib0002] ^,^ [@bib0005] ^,^ [@bib0013] ^,^ [@bib0014]

A notable finding was the higher prevalence of cardiac injury on admission in our patients compared to what was reported in China (38% vs 20%).[@bib0005] ^,^ [@bib0015] Our patient cohort also had a higher prevalence of cardiovascular conditions including hypertension (73% vs 31%), diabetes mellitus (44% vs 14%), and cerebrovascular disease (12% vs 5%). These comorbid conditions were associated with cardiac injury (p \< 0.05), which likely explains the higher incidence of cardiac injury in our cohort. The higher incidence of cardiac injury may also contribute to the higher mortality rates seen in the U.S. cohort. From the available data, ARDS and cardiac injury are noted to be the strongest predictors of need for mechanical ventilation and mortality in patients with COVID-19.[@bib0005] Although data from Wuhan showed cardiac injury on presentation was an independent factor associated with mortality, our current U.S. study did not reproduce similar results. However, our study did show that patients with higher peak hs-cTnI levels during admission had significantly higher rates of mechanical ventilation or death. This suggests that the extent of cardiac injury is associated with outcomes including mortality.

The exact mechanism by which SARS-CoV-2 leads to cardiac injury is not fully elucidated. [Figure 2](#fig0002){ref-type="fig"} illustrates the multiple proposed mechanisms. SARS-CoV-2 infection is mediated through the viral surface spike protein to the human angiotensin-converting enzyme 2 (ACE-2) receptor. [@bib0016] Systemic infection is likely due to entry through pulmonary alveolar ACE-2 receptors, which are also present on the heart, kidneys, vascular endothelium, and others.[@bib0016] ^,^ [@bib0017] During the SARS outbreak, SARS-CoV-1 viral RNA was detected in 35% of hearts on autopsy. [@bib0018] In murine models with previous SARS-CoV-1, cardiac viral infection was mediated by an ACE-2-dependent myocardial viral entry [@bib0019]; it has been proposed that a similar mechanism of cardiac injury exists where SARS-CoV-2 can directly affect cardiac myocytes, inducing myocarditis or pericarditis as supported by case reports of pericardial effusion and tamponade in patients with COVID-19.[@bib0020] ^,^ [@bib0021] An early controversy in the treatment of COVID-19 was whether the renin-angiotensin-aldosterone system blockers confer a higher risk of mortality in these patients. This theory is based on the speculation that these drugs may upregulate the expression of ACE-2 receptors. This, however, is not the case in published cohorts,[@bib0022] including our study. Supply-demand mismatch is another mechanism by which cardiac injury can occur. The severe systemic immune response from infection may lead to increased physiologic stressors resulting in a combination of hypotension, increased metabolic demands, and hypoxia from acute lung injury. This has been historically well described in other disease processes causing sepsis[@bib0023], [@bib0024], [@bib0025], and commonly leads to type II myocardial infarction. Sepsis, inflammation and ARDS are well-known entities that cause coagulation disorders.[@bib0026] Hypercoagulability leading to microthrombi has also been described in patients with COVID-19.[@bib0027] In this study, patients with cardiac injury were more likely to have elevated D-dimer levels (1.9 vs 1.1 µg/ml, p \< 0.001), raising the possibility of microthrombi formation as another mechanism by which cardiac injury occurs. Additionally, new reports of higher incidence of Kawasaki\'s disease in Italy after the COVID-19 pandemic surge [@bib0028] may suggest vascular involvement, which can affect the coronary vessels. Finally, the development of acute coronary syndrome in the setting of infection and heightened cytokine response is possible. A case series from New York identified patients with ST-elevation myocardial infarction in COVID-19 and revealed variability in presentation and presence of obstructive disease, suggesting that myocardial injury could be due to plaque rupture, coronary spasm, or direct endothelial injury.[@bib0029] Confirmation of these proposed mechanisms will require future post-mortem analysis.Figure 2Potential cardiac injury mechanisms in COVID-19. This figure illustrates the proposed mechanisms of cardiac injury in COVID-19. Systemic infection is likely mediated through angiotensin-converting enzyme 2 (ACE-2) receptors found on multiple cell lineages, including the alveolar and cardiac cells. The proposed mechanisms of injury include myopericarditis through direct viral infection or systemic inflammation, hypercoagulability leading to coronary bed microthrombi, vasculitis, stress cardiomyopathy, acute coronary syndrome, and type-II myocardial infarction from supply-demand mismatch.Figure 2

There are multiple strengths and limitations to our study. To date, our study is one of the largest to describe patterns of cardiac injury, particularly from the U.S. The main limitation of this study is the retrospective design. Given the retrospective nature of the analysis and changes in contemporary COVID-19 management, the timing of laboratory blood sampling could not be standardized in all patients. Patients who remain admitted were not included, as our primary outcome could not be assessed. Additionally, hs-cTnI is a biomarker, and categorization of the type of injury and mechanism behind hs-cTnI elevation is not easily determined when performing a retrospective analysis. Larger prospective trials with standardized protocols may better verify these results.

In conclusion, the presence of cardiovascular risk factors was associated with an increased risk of developing cardiac injury in patients admitted with COVID-19. The extent of cardiac injury was associated with worse outcomes, including mortality.
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[^1]: Abbreviations: ACEi = Angiotensin Converting Enzyme Inhibitor; ALT = Alanine Aminotransferase; ARB = Angiotensin II Receptor Blockers; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; COPD = Chronic Obstructive Pulmonary Disease; CPK = Creatine Phosphokinase; CRP = C-Reactive Protein; GFR = Glomerular Filtration Rate; LDH = Lactate Dehydrogenase; WBC = White Blood Cell.

[^2]: Abbreviations: ARDS = Acute Respiratory Distress Syndrome; Hs-cTnI = High Sensitivity Troponin; ICU = Intensive Care Unit.

[^3]: Variables controlled for:

[^4]: Risk factors: Age ≥ 65, Gender, Body Mass Index, Hypertension, Coronary Artery Disease, Heart Failure, Atrial Fibrillation/ Flutter, Cerebrovascular Disease, Immunosuppressed State, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease, Cirrhosis. Inpatient Clinical Data Elements: Peak levels of High Sensitivity Troponin, Lactate Dehydrogenase, C-Reactive Protein, Ferritin and D-dimer levels based on quartiles, Acute Respiratory Distress Syndrome, Acute Kidney Injury
